AchalasiaPOEM RegistryNCT02162589
Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Registry
An observational study of Achalasia, run by Weill Medical College of Cornell University at 1 site in United States.
Trial summary
Prospective Multicenter registry study to assess the safety and efficacy of clinically indicated peroral endoscopic myotomy (POEM) for the treatment of Achalasia Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Achalasia
- What is being tested?
- POEM
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2014to 1 Jan 2018
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia and above or equal to 18 years of age
Who may be able to join
- Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia
- Above or equal to 18 years of age
Who cannot join
- Any patient who has not undergone POEM for the treatment of Achalasia
- Below 18 years of age
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Weill Cornell Medical College
New York, New York, 10021
Michel Kahaleh, MD, 646-962-4797, mkahaleh@gmail.com
Monica R Gaidhane, MD, MPH, 646-962-4796, mog2012@med.cornell.edu
About this study
Official title: Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Retrospective And Prospective Multicenter Registry.
Prospective Multicenter registry study to assess the safety and efficacy of clinically indicated peroral endoscopic myotomy (POEM) for the treatment of Achalasia
Read the detailed description
Our institution performs therapeutic Interventional Endoscopy in around 700-1000 patients a year. We come across several patients with esophageal disorders, including esophageal cancer and Achalasia.
Achalasia is an uncommon esophageal motility disorder caused by the inability of the lower esophageal sphincter (LES) to relax due to the degeneration of inhibitory neurons in the myenteric plexus. (1,2) Evidence of achalasia in patients includes the absence of relaxation in the LES, abnormal swallowing relaxation of the LES, or the absence of peristalsis in the esophageal body.
(2,3 ) Treatments for achalasia primarily focus on forcing the relaxation of the LES. Conventional treatments such as botolinum toxin (Botox) injections, balloon dilation, nitrate and calcium antagonists, and Heller myotomy, although effective, have many disadvantages. (4,5, 6) Balloon dilation, which is the least noninvasive out of the non-surgical processes, can still result in esophageal perforation and its long term investigations have reported unfavorable (2). Surgical myotomies, such as Heller myotomy and laproscopic esophagomytomy, are indicated when non-surgical therapies render ineffective.
However, gastroesophageal reflux disease occurs in 30% (7) of Heller Myotomy patients and it has a 10-15% failure rate (8). Per-oral endoscopic myotomy (POEM), derived from Advances in Natural Orifice Transluminal Endoscopic Surgery (NOTES) and advances in submucosal dissection (9,10,11), presents a novel, less invasive, and permanent treatment to lower esophageal sphincter pressure (12). POEM was first described by Parischa et al in porcine models in 2007 and its introduction into clinical care in 17 patients was made by Inoue et al in 2010. (12,13) POEM is performed entirely endoscopically, enabling much deeper incisions in the thoracic esophagus than surgery is able to create. (2 , 13) An incision is made in the mid- esophagus by creating a submucosal tunnel to access the muscle layer all the way down to the gastric cardia and conduct myotomy (partial muscle removal). Partial inner circular muscle layer is removed from the last part of the esophagus, lower esophageal sphincter and the upper part of the stomach. After the myotomy is completed, endoclips are used to seal the incision and the endoscope is withdrawn. (2) The effectiveness of POEM is indicated by patient studies based mostly in Europe and Asia. Recent studies report POEM has a 90% effectiveness rate compared to patients who have undergone Heller myotomy. (9 ,14,15) Based on study design and results of the recent studies done in Europe and Asia (retrospective only), we would like to evaluate and verify technical feasibility, clinical success and safety of clinically indicated POEM for Achalasia prospectively with a longer follow up duration (more than 6 months). Evaluation of these factors would help us compare them to conventional treatment modalities within our current facility; and consequently help us identify appropriate treatment techniques and improve clinical management of patients at WCMC-NYPH. The purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of POEM. The registry will evaluate technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review.
The procedures we are evaluating are all clinically indicated and will not be prescribed to someone to participate in this registry study.
The purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of POEM. The registry will evaluate technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review.
Study Design: Retrospective and Prospective, observational, medical chart review for at least 6 standard of care visits up to 1 year after subject consents for study participation.
Interventions: None Subject Participation: Subject's participation in this study will allow us to collect data for at least 6 standard of care visits up to 1 year after consenting to participating in this registry study. Subject will undergo a standard of care or clinically indicated Endoscopic procedure and POEM and subsequent follow up clinic visits as part of their standard medical care.
Subject will sign a separate clinical consent for the Endoscopic procedure and placement of the sutures(s). That consent form will explain the procedure as well as the risks involved with the procedure. Subject will undergo endoscopic procedures and POEM and subsequent follow up clinic visits regardless of their participation in this study. Subject will undergo no additional tests and procedures as part of this study.
Study duration: At least 6 standard of care visits up to 1 year for each subject . Once the subject consents, data will be collected for their clinically indicated or standard of care procedure visit and follow up visits.
Research related activities: Consenting, medical chart review and case report form entry.
Clinically indicated and necessary procedures include: Evaluation, imaging, lab tests, adverse events monitoring and POEM.
Standard of care follow up visits for POEM are usually 15 days, 1 month, 3 months, 6 months and 12 months post procedure. All data will be collected from Medical charts. No subject surveys or questionnaires will be administered.
Study Design at Coordinating Center - Primary site (WCMC): T All patients who have had clinically indicated POEM done for Achalasia.
Study Design at Secondary site: Other sites must have either a database review protocol and/or a clinical trial that would collect data on POEM prior to participating in the registry.
These sites would have IRB approved protocols to collect and send procedure data to the primary site (WCMC). Additionally, the secondary study sites would mention WCMC as an entity that could receive PHI in their respective protocols and consent/HIPAA forms. All secondary study sites' IRB approvals will be sent to the primary/coordinating study center for WCMC IRB.
Data sharing agreements will be finalized prior to sharing of any and all confidential data.
Registry Hosting: The coordinating center and primary site (WCMC) will host the registry on the local servers. Electronic Data Capture (EDC) system REDCAP will be used for data entry, compilation and querying. Secondary sites will be trained and a Redcap login ID will be provided. REDCAP data from all sites will be accessible only to the primary coordinating site investigators. The data will be stored on the REDCAP server. Specific access/editing permissions will be granted as per standard protocol to personnel at secondary sites who will enter data.
- Conditions
- Achalasia
- Being tested
- POEM
- Medical subject headings
- Esophageal Achalasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
POEMProcedure or surgery
Per oral endoscopic myotomy
| Study group | Role | What they receive |
|---|---|---|
| POEM for Achalasia | Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia. Receives: Procedure: POEM |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Success
Documentation of clinical success rates such as achievement of symptoms remission (dysphagia, reflux, etc.) and reduced lower esophageal sphincter pressures (manometry).
Measured: 1 year
Secondary outcomes (1)
Safety Rate
Documentation of Safety: Number of subjects with Adverse Events, Type, frequency and intensity of adverse events.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2014 (estimated)
- Study startFeb 2014
- Primary completion1 Dec 2017 (estimated)
- Study completion1 Jan 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AchalasiaStudies of the same condition, open and under way.
- More trials run by Weill Medical College of Cornell UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michel Kahaleh, Weill Medical College of Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02162589
- Sponsor's protocol ID
- 1309014292
- Acronym
- POEM Registry
- Status last verified
- Feb 2017
- First submitted
- 10 Jun 2014
- Last updated
- 20 Feb 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No IPD sharing
Publications
Kumta NA, Mehta S, Kedia P, Weaver K, Sharaiha RZ, Fukami N, Minami H, Casas F, Gaidhane M, Lambroza A, Kahaleh M. Peroral endoscopic myotomy: establishing a new program. Clin Endosc. 2014 Sep;47(5):389-97. doi: 10.5946/ce.2014.47.5.389. Epub 2014 Sep 30.
PubMed 25324996Tyberg A, Seewald S, Sharaiha RZ, Martinez G, Desai AP, Kumta NA, Lambroza A, Sethi A, Reavis KM, DeRoche K, Gaidhane M, Talbot M, Saxena P, Zamarripa F, Barret M, Eleftheriadis N, Balassone V, Inoue H, Kahaleh M. A multicenter international registry of redo per-oral endoscopic myotomy (POEM) after failed POEM. Gastrointest Endosc. 2017 Jun;85(6):1208-1211. doi: 10.1016/j.gie.2016.10.015. Epub 2016 Oct 15.
PubMed 27756611
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Retrospective And Prospective Multicenter Registry.
- ClinicalTrials.gov ID
- NCT02162589
- Acronym / sponsor ID
- POEM Registry / 1309014292
- Conditions
- Achalasia
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Study start
- Feb 2014
- Primary completion
- 1 Dec 2017 (estimated)
- Study completion
- 1 Jan 2018 (estimated)
- First posted
- 12 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective Multicenter registry study to assess the safety and efficacy of clinically indicated peroral endoscopic myotomy (POEM) for the treatment of Achalasia
Detailed description
Our institution performs therapeutic Interventional Endoscopy in around 700-1000 patients a year. We come across several patients with esophageal disorders, including esophageal cancer and Achalasia.
Achalasia is an uncommon esophageal motility disorder caused by the inability of the lower esophageal sphincter (LES) to relax due to the degeneration of inhibitory neurons in the myenteric plexus. (1,2) Evidence of achalasia in patients includes the absence of relaxation in the LES, abnormal swallowing relaxation of the LES, or the absence of peristalsis in the esophageal body.
(2,3 ) Treatments for achalasia primarily focus on forcing the relaxation of the LES. Conventional treatments such as botolinum toxin (Botox) injections, balloon dilation, nitrate and calcium antagonists, and Heller myotomy, although effective, have many disadvantages. (4,5, 6) Balloon dilation, which is the least noninvasive out of the non-surgical processes, can still result in esophageal perforation and its long term investigations have reported unfavorable (2). Surgical myotomies, such as Heller myotomy and laproscopic esophagomytomy, are indicated when non-surgical therapies render ineffective.
However, gastroesophageal reflux disease occurs in 30% (7) of Heller Myotomy patients and it has a 10-15% failure rate (8). Per-oral endoscopic myotomy (POEM), derived from Advances in Natural Orifice Transluminal Endoscopic Surgery (NOTES) and advances in submucosal dissection (9,10,11), presents a novel, less invasive, and permanent treatment to lower esophageal sphincter pressure (12). POEM was first described by Parischa et al in porcine models in 2007 and its introduction into clinical care in 17 patients was made by Inoue et al in 2010. (12,13) POEM is performed entirely endoscopically, enabling much deeper incisions in the thoracic esophagus than surgery is able to create. (2 , 13) An incision is made in the mid- esophagus by creating a submucosal tunnel to access the muscle layer all the way down to the gastric cardia and conduct myotomy (partial muscle removal). Partial inner circular muscle layer is removed from the last part of the esophagus, lower esophageal sphincter and the upper part of the stomach. After the myotomy is completed, endoclips are used to seal the incision and the endoscope is withdrawn. (2) The effectiveness of POEM is indicated by patient studies based mostly in Europe and Asia. Recent studies report POEM has a 90% effectiveness rate compared to patients who have undergone Heller myotomy. (9 ,14,15) Based on study design and results of the recent studies done in Europe and Asia (retrospective only), we would like to evaluate and verify technical feasibility, clinical success and safety of clinically indicated POEM for Achalasia prospectively with a longer follow up duration (more than 6 months). Evaluation of these factors would help us compare them to conventional treatment modalities within our current facility; and consequently help us identify appropriate treatment techniques and improve clinical management of patients at WCMC-NYPH. The purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of POEM. The registry will evaluate technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review.
The procedures we are evaluating are all clinically indicated and will not be prescribed to someone to participate in this registry study.
The purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of POEM. The registry will evaluate technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review.
Study Design: Retrospective and Prospective, observational, medical chart review for at least 6 standard of care visits up to 1 year after subject consents for study participation.
Interventions: None Subject Participation: Subject's participation in this study will allow us to collect data for at least 6 standard of care visits up to 1 year after consenting to participating in this registry study. Subject will undergo a standard of care or clinically indicated Endoscopic procedure and POEM and subsequent follow up clinic visits as part of their standard medical care.
Subject will sign a separate clinical consent for the Endoscopic procedure and placement of the sutures(s). That consent form will explain the procedure as well as the risks involved with the procedure. Subject will undergo endoscopic procedures and POEM and subsequent follow up clinic visits regardless of their participation in this study. Subject will undergo no additional tests and procedures as part of this study.
Study duration: At least 6 standard of care visits up to 1 year for each subject . Once the subject consents, data will be collected for their clinically indicated or standard of care procedure visit and follow up visits.
Research related activities: Consenting, medical chart review and case report form entry.
Clinically indicated and necessary procedures include: Evaluation, imaging, lab tests, adverse events monitoring and POEM.
Standard of care follow up visits for POEM are usually 15 days, 1 month, 3 months, 6 months and 12 months post procedure. All data will be collected from Medical charts. No subject surveys or questionnaires will be administered.
Study Design at Coordinating Center - Primary site (WCMC): T All patients who have had clinically indicated POEM done for Achalasia.
Study Design at Secondary site: Other sites must have either a database review protocol and/or a clinical trial that would collect data on POEM prior to participating in the registry.
These sites would have IRB approved protocols to collect and send procedure data to the primary site (WCMC). Additionally, the secondary study sites would mention WCMC as an entity that could receive PHI in their respective protocols and consent/HIPAA forms. All secondary study sites' IRB approvals will be sent to the primary/coordinating study center for WCMC IRB.
Data sharing agreements will be finalized prior to sharing of any and all confidential data.
Registry Hosting: The coordinating center and primary site (WCMC) will host the registry on the local servers. Electronic Data Capture (EDC) system REDCAP will be used for data entry, compilation and querying. Secondary sites will be trained and a Redcap login ID will be provided. REDCAP data from all sites will be accessible only to the primary coordinating site investigators. The data will be stored on the REDCAP server. Specific access/editing permissions will be granted as per standard protocol to personnel at secondary sites who will enter data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| POEM for Achalasia | – | Procedure: POEMAny patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia and above or equal to 18 years of age
Key inclusion criteria (2 listed)
- Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia
- Above or equal to 18 years of age
Key exclusion criteria (2 listed)
- Any patient who has not undergone POEM for the treatment of Achalasia
- Below 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| POEMPer oral endoscopic myotomy | Procedure or surgery | POEM for Achalasia |
Primary outcome
Clinical Success
Time frame: 1 year
Documentation of clinical success rates such as achievement of symptoms remission (dysphagia, reflux, etc.) and reduced lower esophageal sphincter pressures (manometry).
1 secondary outcome
Safety Rate
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2017.
- Background: PubMed 25324996Kumta NA, Mehta S, Kedia P, Weaver K, Sharaiha RZ, Fukami N, Minami H, Casas F, Gaidhane M, Lambroza A, Kahaleh M. Peroral endoscopic myotomy: establishing a new program. Clin Endosc. 2014 Sep;47(5):389-97. doi: 10.5946/ce.2014.47.5.389. Epub 2014 Sep 30.
- Derived from this study: PubMed 27756611Tyberg A, Seewald S, Sharaiha RZ, Martinez G, Desai AP, Kumta NA, Lambroza A, Sethi A, Reavis KM, DeRoche K, Gaidhane M, Talbot M, Saxena P, Zamarripa F, Barret M, Eleftheriadis N, Balassone V, Inoue H, Kahaleh M. A multicenter international registry of redo per-oral endoscopic myotomy (POEM) after failed POEM. Gastrointest Endosc. 2017 Jun;85(6):1208-1211. doi: 10.1016/j.gie.2016.10.015. Epub 2016 Oct 15.
- Description of POEM procedure for AchalasiaLink provided by the sponsor.
- Individual participant dataSharing planned: No. No IPD sharing
Related trials for Achalasia
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 2
Full-thickness Versus Progressive Myotomy in Peroral Endoscopic Esophageal Myotomy in Achalasia: A Randomized Controlled Trial
Achalasia Cardia, Achalasia
RecruitingPhase 3
PREcision MEDicine In Achalasia (PREMEDIA)
Type I Achalasia, Type II Achalasia
RecruitingObservational study
PREcision MEDicine In Achalasia (PREMEDIA) - Cohort
Type III Achalasia, EGJ Outflow Obstruction With Spastic/Hypercontractile Features
RecruitingPhase 4
VZV in the Enteric Nervous System: Pathogenesis and Consequences
Achalasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Achalasia, run by Weill Medical College of Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Michel Kahaleh, MD (646-962-4797, mik9071@med.cornell.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Success (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02162589, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2017.